Literature DB >> 21106442

The devil's advocacy: when and why inhaled therapies for tuberculosis may not work.

Awadh Bihari Yadav1, Amit K Singh, Rahul K Verma, Mradul Mohan, Atul K Agrawal, Amit Misra.   

Abstract

Factors that are inimical to the success of inhaled therapies for tuberculosis (TB) include: (i) lack of access of inhaled therapies to poorly-aerated areas of the tubercular lung; (ii) limited ability to penetrate biofilms formed by extracellular bacilli; (iii) selection for resistant bacilli on account of administration of low doses of anti-TB agents; (iv) induction of inflammation and/or immunopathology in the airways and lungs; and (v) anomalies in antigen processing and presentation of vaccines delivered to the lungs. Further, the claim that inhaled therapies rescue alternatively-activated macrophages may not be applicable to all individuals. Fortunately, there are ways and means to address each of the above factors.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106442     DOI: 10.1016/j.tube.2010.10.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  2 in total

1.  Nanoparticle-mediated macrophage targeting-a new inhalation therapy tackling tuberculosis.

Authors:  Shaimaa Makled; Nabila Boraie; Noha Nafee
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

2.  An Inhalable Theranostic System for Local Tuberculosis Treatment Containing an Isoniazid Loaded Metal Organic Framework Fe-MIL-101-NH2-From Raw MOF to Drug Delivery System.

Authors:  Gabriela Wyszogrodzka-Gaweł; Przemysław Dorożyński; Stefano Giovagnoli; Weronika Strzempek; Edyta Pesta; Władysław P Węglarz; Barbara Gil; Elżbieta Menaszek; Piotr Kulinowski
Journal:  Pharmaceutics       Date:  2019-12-17       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.